Mannatech Incorporated Common Stock (MTEX)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor who wants a durable business bought at a sensible price. Mannatech sells nutritional supplements, skin care, and weight-management products through network marketing, a model with loyal distributors but no obvious wide moat. The numbers show why caution is warranted. Revenue fell from $132.0M in fiscal 2023 (year ended 2023-12-31) to $117.9M in fiscal 2024 (year ended 2024-12-31) to $108.0M in fiscal 2025 (year ended 2025-12-31). Net income went from a $2.2M loss in fiscal 2023 to $2.5M profit in fiscal 2024, then a $15.2M loss in fiscal 2025. That is a deteriorating trend.

In plain English: Mannatech sells vitamins, skin-care and weight-loss products, mostly through a network-marketing model. The business looks weak: sales have shrunk and it lost money in the latest full year, though the two most recent reported quarters showed small profits. At $7.56 a share, the price does not look clearly cheap or expensive given those mixed results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer